FindTrial
Sign In

selenium supplement field study in Qidong city

prevention of hepatocellular carcinogenesis through selenium supplement in high risk population: a field trial and subsequent follow-up

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-12002836
Enrollment
Unknown
Registered
2012-12-14
Start date
1996-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

selenium supplement:sodium selenite 0.5mg per os daily
placebo control:Placebo per os daily

Sponsors

Qidong liver cancer institute
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
20 Years to 65 Years

Inclusion criteria

Inclusion criteria: 20-65 years old male in Qidong city and HBsAg seropositive

Exclusion criteria

Exclusion criteria: AFP or ALT seropositive

Design outcomes

Primary

MeasureTime frame
incidence of hepatocellular carcinoma;mortality of hepatocellular carcinoma;—

Secondary

MeasureTime frame
ALT;AFP;two pairs of semi - hepatitis;—

Countries

China

Contacts

Public ContactTAOYANG CHEN
ty110@263.com+86 0513-83106001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026